Incannex Healthcare Inc. (IXHL)
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Last price
- $2.91
- As of
Kresmion compiles this page from IXHL's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Incannex Healthcare Inc. (IXHL): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-K filed 2026-09-25.
See the full IXHL dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for IXHL on one page. Preview it with sample data, then open it live with a free account.
Preview the IXHL dossierActive signals for IXHL
- mediumEARNINGS_BEAT
Q4-2026: Beat consensus by 74.1%, EPS $-0.197 vs $-0.762 estimate
- mediumNEW_POSITION
CITADEL ADVISORS LLC new position in IXHL
- mediumNEW_POSITION
MILLENNIUM MANAGEMENT LLC new position in IXHL
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 2316.1% - EPS $-22.83 vs $-0.9449 estimate
- mediumEARNINGS_MISS
Q1-2026: Missed consensus by 2328.8% - EPS $-22.95 vs $-0.9449 estimate
FREE, NO ACCOUNT
Every signal on IXHL, as it fires
You are seeing 5 of 8 signals recorded on IXHL since 2026-06-02.
The five above landed across 3 days. The other 3 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in IXHL (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 45333F208 · 2026Q2 | $358K | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 45333F208 · 2026Q2 | $39K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, IXHL
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
IXHL mentioned in Kresmion daily briefs
IXHL against its peers
IXHL's return on equity of -28.6% ranks in the 39th percentile of 13 Drug Manufacturers - Specialty & Generic sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | IXHL | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 0.0 USD | 35.2M USD | 3 | 14 |
| Gross margin | n/a | 40.1% | n/a | 12 |
| Operating margin | n/a | -21.8% | n/a | 13 |
| Net margin | n/a | -27.9% | n/a | 15 |
| Return on equity | -28.6% | -24.6% | 39 | 13 |
| 1 year | -76.2% | -36.2% | 11 | 13 |
Peers (17): PLNH, ITHUF, RMTI, SCYX, INIS, CXXIF, LEEEF, TLPH, RAPH, CPHI, MRMD, ETST, SHPH, TXMD, CWBHF, AYTU, ZYBT. Left out: GSTK (no annual filing), HSTI (period gap), CPIVF (no annual filing), OPTH (no annual filing), MCUJF (period gap), ROMJF (no annual filing), UPC (period gap), INCR (period gap). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (IXHL: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow IXHL on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to IXHL for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.